Clinical Trial Search

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — -56 percentage change from baseline

Primary: Efficacy as Assessed by 3-year Prostate-specific Antigen Progression-free Survival Rate — 22; 3 Participants

Primary: Median Relapse-Free Survival Time (Biochemical or Clinical) — 45.3 months

Primary: Efficacy as Assessed by 2-year PSA Progression-free Survival Rate — 17 Participants

Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants

Primary: Percentage of Participants With PSA50 Response — 2 Participants

Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g

Primary: Overall Survival — 91.6 weeks

Primary: Change in Tissue Testosterone and Dihydrotestosterone — 0.156 pg/mg

Primary: Mean Prostate Specific Antigen (PSA) Level — 0.61; 0.70; 0.54 ng/mL

Primary: Progression-free Survival (PFS) Based on the RECIST Criteria — 5.5; 3.7 months — p=0.02

Primary: Cancer Detection Performance of FACBC PET/CT — 17; 22; 4; 14 Participants

Primary: Percentage of Patients Who Achieve an Undetectable PSA (=< 0.2 ng/ml) — 0.0 percentage of patients

Primary: Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients…

Primary: Clinical Benefit Rate From Cabozantinib (XL184) — 10 Participants

Primary: Progression Free Survival (PFS) — 12.9; 18.5 Months

Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants

Primary: Measurement of Sensitivity of DCFBC-PET as Determined by Agreement of PET/CT Detection of Metastatic Prostate Cancer With Conventional Imaging Modality (CIM) — 148; 170…

Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale

Primary: Time to First Skeletal Related Event — 31.9; 28.8 months — p=0.385

Primary: Metabolic Syndrome — 0; 0 kilograms

Primary: Gallium Ga 68-DOTATATE Uptake — 11; 4; 1 Participants

Primary: PSA Decline of >= 50% (PSA50) From Baseline — 7.7 percentage of participants

Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 Given Every Two Weeks. — 20 mg/kg every 2 weeks

Primary: Overall Time to Disease Progression — 10.9; 9.9 Weeks — p=0.719

Primary: Number of Tumor Lesions Detected by 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI — 92; 127 number of tumor lesions

Primary: Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR]) — 6.8 percentage of participants

Primary: Count of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months — 10 Participants